Navigation Links
NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill
Date:10/3/2011

LAWRENCE, Mass., Oct. 3, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today applauded the efforts of its home hemodialysis patients together with the National Kidney Foundation (NKF) and Dialysis Patient Citizens (DPC), in advocating for improvements in the quality of care for end stage renal disease (ESRD) patients with lawmakers.  

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

NxStage home hemodialysis patients recently joined a delegation of patient advocates for a series of congressional briefings and meetings in Washington, D.C. Patients stressed the need for important policy changes including the extension of immunosuppressive drug coverage for transplant patients, improved access to more frequent home hemodialysis, and other policies impacting dialysis patients in the U.S.

"These meetings are important opportunities to engage with policymakers and share first-hand the unique challenges dialysis patients face," said Vanessa Evans, Dialysis Patient Citizens member and NxStage home hemodialysis patient. "I feel fortunate to have access to more frequent home dialysis therapy, which is the best option for me and my lifestyle, but there is much to be done to improve education on treatment options and healthcare policy surrounding kidney disease and we look forward to continuing to advocate for the dialysis community."  

"NxStage patients and these advocacy groups are important champions of quality care for dialysis patients," said Jeffrey H. Burbank, chief executive officer of NxStage Medical, Inc. "We commend their continuing efforts to expand access to therapies that can lead to improved quality of life, better health outcomes and associated lower costs for all dialysis patients."

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage's System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Media Contacts:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
2. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
3. NxStage to Present at UBS Global Life Sciences Conference
4. NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award
5. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
6. NxStage® Highlights Non-Medical Emergency Preparedness Guidebook for System One™ Home Hemodialysis Patients
7. NxStage Celebrates Seven Year Anniversary of IU Healths Home Hemodialysis Program and Patient Milestones
8. NxStage Announces Third Quarter 2011 Investor Conference Schedule
9. NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance for 2011
10. NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA
11. NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... 19, 2017 While various ... about reducing the FDA,s regulatory strictness as a ... medical drug industry, many of the leading biotech ... trials and development of advanced drug treatments and ... recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... Top deals by value - Deals listed by company ... The report provides understanding and access to the partnering ... healthcare companies. The report provides an analysis of ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... ... 2017 , ... MB Business Capital, a division of MB ... to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing (“MedPro”). Proceeds ... MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided a new ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for patients with sleep apnea and TMJ disorders. These conditions are quite common ... Dr. Rassouli provides personalized care to reduce the risk of these consequences and ...
(Date:1/19/2017)... ... 2017 , ... Sam & Associates Insurance Agency, a full service firm providing ... California Bay Area, is launching a charity drive to raise awareness of heart disease ... the primary killer of adult men and women in America, and is responsible for ...
(Date:1/19/2017)... ... ... St. Catherine’s Village announced that a limited number of rooms have become available ... grounds of the St. Catherine’s Village campus in Madison, Mississippi that accommodates 120 residents ... Mississippi for the second year in a row by readers of the Clarion-Ledger. , ...
Breaking Medicine News(10 mins):